Cyclacel Limited

Mark Thomas

Peter Martin Fischer

Campbell McInnes

Robert Westwood

Shudong Wang

Nicholas James Westwood

Stuart Donald Jones

Daniella I Zheleva

Janice McLachlan

Kenneth Duncan

Fred Scaerou

Neil McIntyre

Bob Westwood

Campbell Mcinnes

Nicholas Westwood

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR, NHCO, NHSO, NHCH, CH, CHCH, or CH&#x2550;CH; X is a hydrocarbyl group optionally substituted by one or more Rgroups; Rand Rare each independently II or alkyl; R-Rare each independently II or (CII)R, where m is O, 1, 2, or 3; each Ris independently (CH)R, where each Ris independently selected from O(CH)R, R, COR, COOR, CN, CONRR, NRR, NRCOR, SR, SOR, SOR, NRSOR, SOOR, SONRR, halogen, CF, and NO, and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; Rand Rare each independently H or (CH)R, where n is 0, 1, 2, or 3; and each Ris independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO-alkyl, SO-aryl, COOH, CO-alkyl, CO-aryl, NH, NH-alkyl, N(alkyl), CF, alkyl and alkoxy, wherein said alkyl and alkoxy groups may be further substituted by one or more OH groups. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula I, and the use of compounds of formula (I) in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc. 

Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds

A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; 'a' is a single bond; or 'a' is a double bond and one of Rand R, and one of Rand Rare absent; Ris H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO-alkyl, CORand an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from Rand R; Ris H, R, or an alkyl group optionally substituted with one or more Rgroups; R, R, R, and Rare each independently selected from H, R, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more Rgroups; or Rand R, and/or Rand Rtogether represent &#x2550;O; Ris H, R, NH(CH)R, CO(CH)R, NHCO(CH)R, O(CH)R, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from Rand R; Ris OR, NRR, halogen, CF, NO, COR, CN, COOR, CONRR, SORor SONRR; Ris a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more Rgroups; R, R, Rand Rare each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases

Growing community of inventors

Dundee, United Kingdom

Mark Thomas